A new monoclonal antibody to human prostatic acid phosphatase suitable for immunohistology in formalin-fixed paraffin-embedded tissue sections

Haines, A. M. R.; Larkin, S. E.; Heyderman, Eadie

doi:10.1042/bst0151179

Cited by 2 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostatic acid phosphatase was purified by ammonium sulphate precipitation, concanavalin A chromatography and ion exchange chromatography, and a monoclonal antibody to PAP (PASE/4LJ) was produced as previously reported (Haines et al, 1987 …”

Section: Methodsmentioning

confidence: 99%

“…The aim of this study was to investigate the possible use for routine immunohistopathological diagnosis of a monoclonal anti-human prostatic acid phosphatase monoclonal antibody, PASE/4LJ (Haines et al, 1987), by examining its reactivity towards a wide variety of prostatic and nonprostatic normal and malignant tissues. We also examined whether the antibody had any inhibitory effect on PAP enzyme activity, to determine if it could be of any potential in an immuno-assisted enzyme assay.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

Haines

Larkin²,

Richardson³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

Summary A murine monoclonal antibody PASE/4LJ to prostatic acid phosphatase (PAP) was used to immunostain a wide variety of sections of benign and malignant tissues (654 blocks). Non-neoplastic adult and fetal prostatic glands, primary and metastatic prostatic carcinomas, and scattered cells in prostatic and penile urethra were positive. Rat, dog and rabbit prostates were negative. Nine of 400 tumours of non-prostatic origin showed some positivity: 6/36 carcinoids, 1/9 islet cell tumours, 1/55 ovarian adenocarcinomas (serous) and one carcinosarcoma of the lung (epithelial portion). Positive staining was seen in islet cells in 4/5 specimens of normal pancreas, and in 4/9 blocks of normal pancreas surrounding a pancreatic tumour. Loops of Henle, maculae densae, and distal tubules in 10/10 fetal and 2/9 adult kidneys were also positive, with proximal tubules and collecting ducts negative. All other 159 blocks of non-neoplastic adult and fetal tissues were negative. The antibody was also affinity purified from ascitic fluid, and shown not to inhibit the enzyme activity of prostatic acid phosphatase.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

Haines

Larkin²,

Richardson³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…A formalin fixed carcinoma of the colon was used for CEA, a carcinoma of the breast for EMA, and a papillary carcinoma of the thyroid for CAM 5.2. The negative control antibody was PASE/4LJ, an IgG 1 mouse monoclonal antibody to prostatic acid phosphatase, which can be used to stain formalin or methacarnfixed tissue of prostatic origin and does not stain benign or malignant breast tissue (Haines et al, 1987).…”

Section: Methodsmentioning

confidence: 99%

Response of breast carcinoma to endocrine therapy predicted using immunostained pelleted fine needle aspirates

Heyderman

Ebbs²,

Larkin³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

Summary Fine needle aspirates from 82 patients with breast carcinoma were fixed in methacarn, double embedded in agar or gelatin, and then in paraffin wax. Sequential sections were stained with monoclonal antibodies to the oestrogen receptor-related protein P29 (antibody D5), carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA) and cytokeratin (CAM 5.2). Sixty-one of 82 (74%) aspirates provided sections suitable for immunostaining. Twenty-six (43%) were D5 positive, 23 (38%) CEA positive, 59 (97%) EMA positive, and 54 (89%) CAM 5.2 positive. Twenty-six of these patients were treated with some form of endocrine therapy. Twelve (46%) showed positive staining for D5. Eleven (92%) of the 12 D5-positive patients responded or had static disease, and 8% progressed. Of the 14 D5-negative tumours 43% responded or remained static, and 57% progressed. The difference in response between the D5-positive and the D5-negative tumours was significant (P<0.05, Fisher's exact test). There was no correlation between staining for CEA, EMA or cytokeratin and response to endocrine therapy.Biochemical estimation of the oestrogen receptor (ER) content of breast tumours is a well established predictor both of response to endocrine therapy and of survival (Seibert & Lippman, 1982;Witliff, 1984 Greene, 1984) and related proteins (King et al., 1985) are now available. The mouse monoclonal antibody D5 directed against the oestrogen receptor-related protein, P29, can be used to immunostain paraffin embedded material fixed in alcohol or in methacarn, without enzyme predigestion (King et al., 1985;Cano et al., 1986). The rat monoclonal antibody directed against the nuclear oestrogen receptor protein (ERICA antibody, Abbott Laboratories, Chicago, USA) requires either fresh unfixed tissue or DNAse pretreatment of paraffin embedded sections (Shintaku & Said, 1987).There have been reports of the predictive value of staining with other antibodies. It has been stated that the presence of carcinoembryonic antigen (CEA) (Shousha et al., 1979;Walker, 1980), and the intensity of staining for a material similar to the large glycoprotein, termed epithelial membrane antigen (EMA) (Heyderman et al., 1985), using monoclonal antibodies HMFG1 (Wilkinson et al., 1984) Although smears prepared from fine needle aspirates have been used for the immunocytochemical localisation of oestrogen receptor and related proteins (Flowers et al., 1986;Cavailles et al., 1987;Coombes et al., 1987), these preparations are unsuitable for the comparative demonstration of multiple markers due to the variation in number of cells per slide, and limitations in the number of slides that can be prepared from a single aspirate. An alternative approach has been to expel the aspirates into tissue culture medium, and make cytospin preparations on polylysine coated slides (Hawkins et al., 1988 The aim of this study was to evaluate a quick and easy method suitable for a busy outpatient clinic, which would allow samples to be sent through the post for further processing, with no ...

show abstract

A new monoclonal antibody to human prostatic acid phosphatase suitable for immunohistology in formalin-fixed paraffin-embedded tissue sections

Cited by 2 publications

References 1 publication

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

Response of breast carcinoma to endocrine therapy predicted using immunostained pelleted fine needle aspirates

Contact Info

Product

Resources

About